Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Phosphorus containing other than solely as part of an...
Reexamination Certificate
2008-06-17
2008-06-17
Berch, Mark L (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Phosphorus containing other than solely as part of an...
C544S118000, C544S244000, C544S265000, C544S276000, C544S277000, C514S234200, C514S263200, C514S263220, C514S263230, C514S263380, C514S263400
Reexamination Certificate
active
07388002
ABSTRACT:
Compounds represented by the formula:A is (CH2)nR2, —CH═CH2, CH2—CH═CH2, O(CH2)nR2, CH(OH)CH3, CH(OH)CH2OH, CH2—CH(OH)CH3, CH2CH(OH)CH2OH, or CH(OH)CH(OH)CH3,R,R1individually is H, NH2OH, Cl, Br, I, aryl, substituted aryl, heterocycle, NR3R4, OR3or SR3,R2is H, OH, F, N3, NH2, CO2H, SH, alkyl, substituted alkyl, S-alkyl, O-acyl, CONH2, or CONH-alkyl,n is 1-3,y is O, S or NH,W is O or S,Z, Z′ individually is OR3, OR4, O(CH2)m—O—(CH2)xCH3, NH—CH(alkyl)CO2R3, alkyl, substituted alkyl, OCH2CH2S—C(O)CH3, OCH2CH2S—C(O)CH(CH3)2, OCH2CH2S—C(O)C(CH3)3, OCH2CH2—SC(O)aryl, OCH2CH2—S—S—OCH2CH2OH, OCH2OC(O)C(CH3)3, OCH2—O—C(O)OCH(CH3)2, or OCH2—O—C(O)CH(CH3)2R3, R4individually is H, alkyl, substituted alkyl, aryl, or substituted aryl;Both R3and R4can form a monocyclic ring of 4-7 atoms with N or optionally a further heteroatom in the ring;m is 1-3,x is 0-19;and pharmaceutically acceptable salts thereof and prodrugs thereof are provided.
REFERENCES:
patent: 5650510 (1997-07-01), Webb et al.
patent: 6057305 (2000-05-01), Holy et al.
patent: 2004/0014722 (2004-01-01), Babu et al.
patent: 2005/0009043 (2005-01-01), Becker et al.
patent: 2005/0033051 (2005-02-01), Babu et al.
patent: 2005/0059637 (2005-03-01), Krawczyk
patent: 2005/0080053 (2005-04-01), Babu et al.
patent: 2008/0008682 (2008-01-01), Chong et al.
patent: 0 206 459 (1986-12-01), None
patent: 0 269 947 (1988-06-01), None
patent: WO 2004106350 (2004-12-01), None
PERBOST M. Nucleosides & nucleotides 1992, vol. 11, No. 8, pp. 1529-1537.
He, et al. Tetrahedron 65 8505 (2005).
Schaeffer, J. Med. Chem 15, 456 (1972).
Wu et al, Nucleosides, Nucleotides & Nucleic Acids (Oct. 2005), 24(10-12), 1543-1568.
Wu et al, Nucleosides, Nucleotides & Nucleic Acids (Oct. 2005), 24(10-12), 1597-1611.
Wu et al, Nucelosides, Nucleotides & Nucleic Acids (Oct. 2005), 24(10-12), 1569-1585.
“Synthesis of Acyclic Nucleoside and Nucleotide Analogues from Amino Acids: A Convenient Approach to a PMEA-PMPA Hybrid” Jeffrey et al.,Tetrahedronvol. 56, No. 29, Jul. 14, 2000, pp. 5077-5083.
“Synthesis and Antiviral Activity of Methyl Derivatives of 9-[2-(Phosphonomethoxy)ethyl]guanine” Yu et al.,Journal of Medicinal Chemistry, vol. 35, No. 16, Aug. 17, 1992, pp. 2958-2969.
“Acyclic Purine Phosphonate Analogues as Antiviral Agents. Synthesis and Structure-Activity Relationships” Kim et al.Journal of Medicinal Chemistryvol. 33, No. 4, Apr. 1990, pp. 1207-1213.
XP-002116171 “Acyclic nucleotide analogs. IV. Phosphonylmethoxyalkyl and Phosphonylalkyl Derivatives of Adenine” Rosenberg et al.,Collection of Czechoslovak Chemical Communications, Institute of Organic Chemistry and Biochemistry, vol. 53, No. 11B, 1988, pp. 2753-2777.
Babu Yarlagadda S.
Chand Pooran
El-Kattan Yahya
Wu Minwan
Berch Mark L
BioCryst Pharmaceuticals Inc.
Connolly Bove & Lodge & Hutz LLP
LandOfFree
Nucleosides, preparation thereof and use as inhibitors of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Nucleosides, preparation thereof and use as inhibitors of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nucleosides, preparation thereof and use as inhibitors of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2813926